Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma

So-Yeon JEON; Ho-Young YHIM; Na-Ri LEE; Eun-Kee SONG; Jae-Yong KWAK; Chang-Yeol YIM.
The Korean Journal of Internal Medicine ; : 365-368, 2017.
Artículo en Inglés | WPRIM | ID: wpr-223229

Documentos relacionados

  1. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
  2. Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma.
  3. Heavy Metal Enlightens Tumor Immunity.
  4. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
  5. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
  6. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
  7. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
  8. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
  9. A Step Ahead in Metastatic Renal Cell Carcinoma.
  10. Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response.